Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience
Omar K. Siddiqi(Boston University), Frederick L. Ruberg(Boston University), Gheorghe Doros(Boston University), Lawreen H. Connors(Boston University), Yuliya Mints(Boston University), Shivangi Kataria(Indian Institute of Technology Mandi), Deepa M. Gopal(Boston University), Graham Lohrmann(Boston University), Alexandra Pipilas(Boston University), John L. Berk(Boston University)
Cited by 46
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615